MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bcr-2023-259057

Медицинская библиотека · BMJ case reports · 2024

Immune checkpoint inhibitor associated diarrhoea.

Al-Hussainy Amin, Adams Joss, Simmons Jon, Kennedy James

СтатьяКлинический случайПеревод в очереди

Аннотация

A man in his 80s was undergoing immunotherapy with pembrolizumab, an anti-PD-1 monoclonal antibody, following his diagnosis of adenocarcinoma of primary lung origin. 24 weeks into treatment, the patient reported experiencing loose stools associated with malaise and poor appetite but no further symptoms. This progressed in frequency and a clinical diagnosis of grade 2 immune checkpoint inhibitor colitis was made. Management with oral prednisolone was commenced but symptoms persisted. Common enteric infections had been ruled out, as were coeliac disease and hyperthyroidism. Flexible sigmoidoscopy and colonoscopy results were not in keeping with colitis, having revealed normal looking mucosa. Following this, a faecal elastase level was found to be low. A diagnosis of pembrolizumab-induced pancreatic exocrine insufficiency was made, and stool frequency and consistency swiftly improved following the use of pancreatic enzyme replacement therapy.

Для цитирования: Al-Hussainy Amin, Adams Joss, Simmons Jon, Kennedy James. Immune checkpoint inhibitor associated diarrhoea.. BMJ case reports. 2024. DOI: 10.1136/bcr-2023-259057.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.